🇺🇸 FDA
Pipeline program

TD-8954

0095

Phase 1 small_molecule terminated

Quick answer

TD-8954 for Gastrointestinal Motility Disorder is a Phase 1 program (small_molecule) at Theravance Biopharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Theravance Biopharma
Indication
Gastrointestinal Motility Disorder
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials